4-[2-(5-氯-2-甲氧基苯甲酰氨基)乙基]苯磺酰胺
中文名称 | 4-[2-(5-氯-2-甲氧基苯甲酰氨基)乙基]苯磺酰胺 |
---|---|
中文同义词 | 4-[2-(2-甲氧基-5-氯苯甲酰胺基)乙基]苯磺酰胺;5-氯-2-甲氧基-N-[2-对氨磺酰苯基)乙基]苯甲酰氨;N-{2-[4-(氨磺酰基)苯基]乙基}-5-氯-2-甲氧基苯甲酰胺;格列本脲USP RC A;格列本脲(优降糖)杂质A;4-[2-(5-氯-2-甲氧基-苯甲酰氨基)乙基]苯磺酰胺;格列本脲杂质A(EP);格列本脲相关化合物A(USP) |
英文名称 | 4-(2-(5-Chloro-2-methoxybenzamido)ethyl)benzenesulfamide |
英文同义词 | 4-(2-(5-Chloro-2-methoxybenzamido)ethyl)benzenesulfamide;Glyburide Related Compound A (25 mg) (5-chloro-2-methoxy-N-[2-(4-sulfamoylphenyl)ethyl]benzamide);4-[2-(2-Methoxy-5-chlorobenzene-1-carboxaMido)ethyl]benzenesulfonaMide;5-Chloro-N-(p-sulfaMoylphenethyl)-o-anisaMide;GlibenclaMide (Glyburide) IMpurity A;Glyburide Related CoMpound A;Glyburide Related Compound A (25 mg) (4-[2-(5-chloro-2-methoxybenzamido)ethyl]benzenesulfonamide);Glyburide USP RC A |
CAS号 | 16673-34-0 |
分子式 | C16H17ClN2O4S |
分子量 | 368.84 |
EINECS号 | 240-722-5 |
相关类别 | 磺胺类药物/亚磺酰胺;磺胺类药物;亚磺酰胺;中间体;有机化学;Organic Building Blocks;Sulfonamides/Sulfinamides;Sulfur Compounds;Aromatics;Pharmaceuticals;Aromatics,Pharmaceuticals;Building Blocks;Chemical Synthesis;Organic Building Blocks;Sulfur Compounds;Intermediates & Fine Chemicals |
Mol文件 | 16673-34-0.mol |
结构式 |
4-[2-(5-氯-2-甲氧基苯甲酰氨基)乙基]苯磺酰胺 性质
熔点 | 209-214 °C |
---|---|
密度 | 1.356±0.06 g/cm3(Predicted) |
储存条件 | 2-8°C |
溶解度 | 溶于DMSO(高达45mg/ml)。 |
形态 | 固体 |
酸度系数(pKa) | 10.14±0.10(Predicted) |
颜色 | 白色 |
稳定性 | DMSO中的溶液可在-20°下稳定储存3个月。 |
CAS 数据库 | 16673-34-0(CAS DataBase Reference) |
4-[2-(5-氯-2-甲氧基苯甲酰氨基)乙基]苯磺酰胺的制备可采用水杨酸为起始物料,水杨酸在光照下以氯气氯化,生成5-氯水杨酸,然后以硫酸二甲酯甲基化得5-氯-2-甲氧基苯甲酸,将后者以氯化亚硫酰氯化,得5-氯-2-甲氧基苯甲酰氯,再与苯胺缩合,产物为N-苯乙基-5-氯-2-甲氧基苯甲酰胺,进而以氯磺酸氯磺化、氨水胺化制得该品。
也可以2-甲氧基-5-氯-苯甲酸为原料,先与氯化亚砜、甲醇作用生成2-甲氧基-5-氯-苯甲酸甲酯,然后与苯乙胺缩合,所得酰胺经氯磺化、肼解后得目标产物4-[2-(5-氯-2-甲氧基苯甲酰氨基)乙基]苯磺酰胺。其制备路线图如下:
图1 4-[2-(5-氯-2-甲氧基苯甲酰氨基)乙基]苯磺酰胺制备路线图
NLRP3 Inflammasome Inhibitor I是合成格列本脲的中间底物,它是NLRP3 inflammasome的抑制剂。Target | Value |
NLRP3 inflammasome
() |
NLRP3-IN-2 is well tolerated with no effects on the glucose levels in vivo.
NLRP3-IN-2 (100 mg/kg) treatment in a model of AMI due to ischemia+reperfusion significantly inhibits the activity of inflammasome (caspase-1) in the heart by 90% (P<0.01) and reduced infarct size, measured at pathology (by >40%, P<0.01) and with troponin I levels (by >70%, P<0.01) .
Animal Model: | Experimental acute myocardial infarction (AMI) model in mice. |
Dosage: | 100 mg/kg. |
Administration: | Intraperitoneal administration 30 minutes prior to surgery, then every 6 hours for 3 additional doses. |
Result: |
Led to a significant >90% reduction in caspase-1 activity (reflective of the formation of an active inflammasome) in the heart tissue measured 24 hours after ischemia.
Led to a significant reduction in the infarct size measured with TTC (>40% reduction) or troponin I levels (>70% reduction) when compared with vehicle alone. |
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/08/19 | HY-W011082 | 4-[2-(5-氯-2-甲氧基苯甲酰氨基)乙基]苯磺酰胺 NLRP3-IN-2 | 16673-34-0 | 50mg | 450元 |
2024/08/19 | HY-W011082 | 4-[2-(5-氯-2-甲氧基苯甲酰氨基)乙基]苯磺酰胺 NLRP3-IN-2 | 16673-34-0 | 10mM * 1mLin DMSO | 500元 |